⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8977638 | 0.81 | P2RX7 (0.61) | — | |
| SCHEMBL28293 | 0.79 | — | — | |
| SCHEMBL2538334 | 0.79 | — | — | |
| SCHEMBL31605465 | 0.79 | — | — | |
| SCHEMBL9515082 | 0.78 | P2RX7 (0.53) | — | |
| SCHEMBL24786819 | 0.77 | P2RX7 (0.57) | — | |
| SCHEMBL667511 | 0.77 | — | — | |
| SCHEMBL971441 | 0.77 | — | — | |
| SCHEMBL22288333 | 0.77 | P2RX7 (0.57) | — | |
| Hydrochloric Acid SCHEMBL11797023 | 0.77 | P2RX7 (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713018-A1 | TRANSFECTION COMPOSITIONS SUITABLE FOR PRODUCING A BIOLOGICAL PRODUCT | PolyPlus Transfection (FR) | 2026-03-25 | — | — | EP | disclosed |
| US-20260042749-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4638436-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-10-29 | — | — | EP | disclosed |
| WO-2024236194-A1 | TRANSFECTION COMPOSITIONS SUITABLE FOR PRODUCING A BIOLOGICAL PRODUCT | POLYPLUS TRANSFECTION (FR) | 2024-11-21 | — | — | WO | disclosed |
| US-20240254118-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-08-01 | — | — | US | disclosed |
| WO-2024137852-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-02-22 | — | — | US | disclosed |
| CN-111902419-B | Novel nucleosides or nucleotide derivatives and use thereof | ST制药株式会社 | 2023-11-24 | — | — | CN | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| WO-2015025018-A1 | NEW BIS-AMIDO PYRIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-02-26 | — | — | WO | disclosed |
| CN-101981033-B | Substituted imidazopyridazines useful as kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2015-02-04 | — | — | CN | disclosed |
| CN-104011053-A | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators | GLAXOSMITHKLINE LLC | 2014-08-27 | — | — | CN | disclosed |
| WO-2013169907-A1 | ALPHA 7 NICOTINIC ACETYLCHOLINE ALLOSTERIC MODULATORS, THEIR DERIVATIVES AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-11-14 | — | — | WO | disclosed |
| CN-101981033-A | Substituted imidazopyridazines useful as kinase inhibitors | BRISTOL MYERS SQUIBB CO | 2011-02-23 | — | — | CN | disclosed |
| WO-2010100475-A1 | HYDROXAMIC ACID DERIVATIVES AS GRAM-NEGATIVE ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2010-09-10 | — | — | WO | disclosed |
| US-20080214552-A1 | Substituted Pyridazinecarboxamides and Derivatives Thereof | BAYER CROPSCIENCE AG (DE) | 2008-09-04 | — | — | US | disclosed |
| CN-100349895-C | Pyrrolopyridazine derivatives | ASTELLAS PHARMA INC (JP) | 2007-11-21 | — | — | CN | disclosed |
| CN-1759117-A | Pyrrolopyridazine derivatives | ASTELLAS PHARMA INC (JP) | 2006-04-12 | — | — | CN | disclosed |
| US-3935211-A | CNS DEPRESSANT | AMERICAN CYANAMID COMPANY (US) | 1976-01-27 | — | — | US | disclosed |